Feb 23, 2022
Dr. Raymond Bergan, Deputy
Director at the University of Nebraska Medical Center Fred and
Pamela Buffet Cancer Center and Professor in both UNMC’s
Eppley Institute for Research in Cancer and the Division of
Oncology and Hematology in the Department of Internal
Medicine, joins Innovators to share his assessment of the state of
cancer research and what may be reasonably expected within the near
began his career at Northwestern University where he served as
Director of Experimental Therapeutics and Leader of the Prevention
Program for the University’s Lurie Comprehensive Cancer Center. In
addition to breakthrough work on early-phase cancer
chemo-prevention, he demonstrated a new way for measuring
prevention therapy in the individual cancer patient, important
steps toward precision medicine and personalized
In 2015, Dr.
Bergan was recruited to join the Oregon Health & Science
University as Head of hematology and oncology and as Associate
Director of medical oncology for the Knight Cancer Institute at
OHSU. There too he led work that enabled individualized patient
treatment with greater precision of effectiveness in ways that can
change how cancer is treated henceforth.
In late 2020, Dr.
Bergan joined the University of Nebraska Medical Center.
degree is from the State University of New York at Buffalo and he
earned the M.D. from the SUNY Health Science Center at Syracuse,
where he also completed his internship and residency. He was
awarded two fellowships in the National Cancer Institute of the
National Institutes of Health.
Innovators is a
podcast production of Harris Search Associates.
*The views and
opinions shared by the guests on Innovators do not necessarily
reflect the views of the interviewee's institution or